These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 1631786)
21. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism]. Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355 [TBL] [Abstract][Full Text] [Related]
22. Altered fibrinolysis in DVT: influence of site of sampling. Han P; Koay ES; Tsakok M; Aw TC; Wong LY; Pradhan M Thromb Haemost; 1988 Aug; 60(1):50-3. PubMed ID: 3142091 [TBL] [Abstract][Full Text] [Related]
23. [Influence of aging and circadian fluctuation of fibrinolytic factors to the responses of these factors during venous occlusion test in healthy subjects]. Motohashi F; Masui Y; Kamogawa A; Hayashi T; Miyake F; Murayama M; Sugai J; Yasumuro Y Rinsho Byori; 1992 Feb; 40(2):172-8. PubMed ID: 1583790 [TBL] [Abstract][Full Text] [Related]
24. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Declerck PJ; Mombaerts P; Holvoet P; De Mol M; Collen D Thromb Haemost; 1987 Dec; 58(4):1024-9. PubMed ID: 3127914 [TBL] [Abstract][Full Text] [Related]
25. Fibrinolytic response to venous occlusion for 10 and 20 minutes in healthy subjects and in patients with deep vein thrombosis. Petäjä J Thromb Res; 1989 Oct; 56(2):251-63. PubMed ID: 2515609 [TBL] [Abstract][Full Text] [Related]
26. Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis? Gram J; Sidelmann J; Jespersen J Thromb Haemost; 1995 Aug; 74(2):718-21. PubMed ID: 8585012 [TBL] [Abstract][Full Text] [Related]
27. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease. Sultan Y; Loyer F; Venot A Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100 [TBL] [Abstract][Full Text] [Related]
28. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females. Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623 [TBL] [Abstract][Full Text] [Related]
29. Fibrinolysis and spinal injury. Relationship to post-traumatic deep vein thrombosis. Petäjä J; Myllynen P; Rokkanen P; Nokelainen M Acta Chir Scand; 1989; 155(4-5):241-6. PubMed ID: 2508383 [TBL] [Abstract][Full Text] [Related]
30. Tissue plasminogen activator release in chronic venous hypertension due to heart failure. Keber I; Keber D; Stegnar M; Vene N Thromb Haemost; 1992 Sep; 68(3):321-4. PubMed ID: 1440498 [TBL] [Abstract][Full Text] [Related]
31. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814 [TBL] [Abstract][Full Text] [Related]
32. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease. Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599 [TBL] [Abstract][Full Text] [Related]
33. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Keber D; Stegnar M; Kluft C Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049 [TBL] [Abstract][Full Text] [Related]
34. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor]. Köhler M; Miyashita C Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347 [TBL] [Abstract][Full Text] [Related]
35. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147 [TBL] [Abstract][Full Text] [Related]
36. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
37. [The fibrinolytic system in patients with dilated myocardiopathy]. Fernández P; Marín F; Marco P; Roldán V; García MC; Martínez JG; Sogorb F; Calatayud R Sangre (Barc); 1996 Oct; 41(5):351-5. PubMed ID: 9026920 [TBL] [Abstract][Full Text] [Related]
38. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039 [TBL] [Abstract][Full Text] [Related]
39. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Glueck CJ; Glueck HI; Welch M; Freiberg R; Tracy T; Hamer T; Stroop D Thromb Haemost; 1994 Feb; 71(2):195-8. PubMed ID: 8191398 [TBL] [Abstract][Full Text] [Related]
40. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis. Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]